Ophthalmologic Vascular Endothelial Growth Factor (VEGF) Inhibitors (for Indiana Only)
Defines medical benefit coverage and medical necessity criteria for intravitreal VEGF inhibitors and dual VEGF/Ang-2 inhibitors for UnitedHealthcare Community Plan members in Indiana.
Coverage Rationale: Added language to indicate Susvimo (ranibizumab) is proven and medically necessary for the treatment of diabetic retinopathy (DR) in patients who previously responded to 2 intravitreal injections of a VEGF inhibitor medication.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.